603127 昭衍新药
已收盘 12-05 15:00:00
资讯
新帖
简况
昭衍新药(06127)选举李叶为职工董事
智通财经 · 21:58
昭衍新药(06127)选举李叶为职工董事
昭衍新药：11月28日高管于爱水减持股份合计8500股
证券之星 · 12-01
昭衍新药：11月28日高管于爱水减持股份合计8500股
昭衍新药：11月26日高管孙云霞减持股份合计10万股
证券之星 · 11-27
昭衍新药：11月26日高管孙云霞减持股份合计10万股
每周股票复盘：昭衍新药（603127）董事高大鹏减持1.0万股
证券之星 · 11-23
每周股票复盘：昭衍新药（603127）董事高大鹏减持1.0万股
昭衍新药：11月20日高管高大鹏减持股份合计10000股
证券之星 · 11-21
昭衍新药：11月20日高管高大鹏减持股份合计10000股
昭衍新药(06127)获股东顾美芳解除质押140万股
智通财经网 · 11-17
昭衍新药(06127)获股东顾美芳解除质押140万股
每周股票复盘：昭衍新药（603127）拟取消监事会并修改章程
证券之星 · 11-16
每周股票复盘：昭衍新药（603127）拟取消监事会并修改章程
昭衍新药：11月12日至11月13日高管高大鹏、孙云霞减持股份合计10.5万股
证券之星 · 11-14
昭衍新药：11月12日至11月13日高管高大鹏、孙云霞减持股份合计10.5万股
每周股票复盘：昭衍新药（603127）Q3净利降80.11%，拟取消监事会
证券之星 · 11-02
每周股票复盘：昭衍新药（603127）Q3净利降80.11%，拟取消监事会
港股异动 | 昭衍新药(06127)涨超4% 前三季度归母净利润8070.61万元
智通财经 · 10-31
港股异动 | 昭衍新药(06127)涨超4% 前三季度归母净利润8070.61万元
昭衍新药（603127）披露拟取消监事会并由审计委员会行使职权，10月30日股价上涨1.7%
证券之星 · 10-30
昭衍新药（603127）披露拟取消监事会并由审计委员会行使职权，10月30日股价上涨1.7%
图解昭衍新药三季报：第三季度单季净利润同比下降80.11%
证券之星 · 10-30
图解昭衍新药三季报：第三季度单季净利润同比下降80.11%
昭衍新药(06127)股东顾美芳解除质押700万股股份
智通财经 · 10-29
昭衍新药(06127)股东顾美芳解除质押700万股股份
昭衍新药（603127）披露董事会召开日期，10月17日股价下跌1.81%
证券之星 · 10-17
昭衍新药（603127）披露董事会召开日期，10月17日股价下跌1.81%
港股异动 | 昭衍新药(06127)涨超3% 近日助力益科思特创新双特异性抗体YK012获批美国FDA IND
智通财经 · 10-15
港股异动 | 昭衍新药(06127)涨超3% 近日助力益科思特创新双特异性抗体YK012获批美国FDA IND
每周股票复盘：昭衍新药（603127）高管减持9.45万股
证券之星 · 10-12
每周股票复盘：昭衍新药（603127）高管减持9.45万股
昭衍新药：9月30日高管高大鹏、孙云霞、顾静良、李叶减持股份合计9.45万股
证券之星 · 10-09
昭衍新药：9月30日高管高大鹏、孙云霞、顾静良、李叶减持股份合计9.45万股
FIDELITY FUNDS减持昭衍新药(06127)44.57万股 每股作价约24.39港元
智通财经 · 09-25
FIDELITY FUNDS减持昭衍新药(06127)44.57万股 每股作价约24.39港元
9月23日昭衍新药跌6.04%，易方达创新驱动灵活配置混合基金重仓该股
证券之星 · 09-23
9月23日昭衍新药跌6.04%，易方达创新驱动灵活配置混合基金重仓该股
昭衍新药遭富达国际减持161.08万股 每股均价约21.57港元
新浪港股 · 09-22
昭衍新药遭富达国际减持161.08万股 每股均价约21.57港元
加载更多
公司概况
公司名称：
北京昭衍新药研究中心股份有限公司
所属行业：
研究和试验发展
上市日期：
2017-08-25
主营业务：
北京昭衍新药研究中心股份有限公司的主营业务是以药物非临床安全性评价服务为主的药物临床前研究服务和实验动物及附属产品的销售业务。公司的主要产品是药物非临床研究服务、临床服务及其他、实验模型供应。
发行价格：
12.51
{"stockData":{"symbol":"603127","market":"SH","secType":"STK","nameCN":"昭衍新药","latestPrice":27.84,"timestamp":1764918001000,"preClose":27.86,"halted":0,"volume":10702205,"delay":0,"changeRate":-0.0007,"floatShares":630000000,"shares":749000000,"eps":0.3004,"marketStatus":"已收盘","change":-0.02,"latestTime":"12-05 15:00:00","open":27.95,"high":27.99,"low":27.41,"amount":297000000,"amplitude":0.0208,"askPrice":27.85,"askSize":59,"bidPrice":27.84,"bidSize":239,"shortable":0,"etf":0,"ttmEps":0.3004,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1765157400000},"marketStatusCode":5,"adr":0,"adjPreClose":27.86,"symbolType":"stock","openAndCloseTimeList":[[1764898200000,1764905400000],[1764910800000,1764918000000]],"highLimit":30.65,"lowLimit":25.07,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":749477334,"isCdr":false,"pbRate":2.57,"roa":"--","peRate":92.676431,"roe":"1.0%","epsLYR":0.1,"committee":0.539059,"marketValue":20865000000,"turnoverRate":0.017,"status":1,"hkstockBrief":{"symbol":"06127","market":"HK","secType":"STK","nameCN":"昭衍新药","latestPrice":16.3,"timestamp":1764922148006,"preClose":16.25,"halted":0,"volume":1228856,"delay":0,"premium":"-46.85"},"floatMarketCap":17553000000},"requestUrl":"/m/hq/s/603127","defaultTab":"news","newsList":[{"id":"2589781882","title":"昭衍新药(06127)选举李叶为职工董事","url":"https://stock-news.laohu8.com/highlight/detail?id=2589781882","media":"智通财经","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2589781882?lang=zh_cn&edition=full","pubTime":"2025-12-05 21:58","pubTimestamp":1764943103,"startTime":"0","endTime":"0","summary":"智通财经APP讯，昭衍新药(06127)公布，于2025年12月5日举行的公司工会委员会会议选举李叶女士为公司职工董事，任期自工会委员会会议选举之日至第五届董事会任期届满为止。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1378402.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["06127","603127","BK1576","BK0216","BK1141"],"gpt_icon":0},{"id":"2588725074","title":"昭衍新药：11月28日高管于爱水减持股份合计8500股","url":"https://stock-news.laohu8.com/highlight/detail?id=2588725074","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2588725074?lang=zh_cn&edition=full","pubTime":"2025-12-01 18:01","pubTimestamp":1764583317,"startTime":"0","endTime":"0","summary":"证券之星消息，根据12月1日市场公开信息、上市公司公告及交易所披露数据整理，昭衍新药最新董监高及相关人员股份变动情况：2025年11月28日公司财务总监于爱水共减持公司股份8500.0股，占公司总股本为0.0011%。变动期间公司股价上涨0.11%，11月28日当日收盘报27.93元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025120100024128.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0216","06127","BK1576","603127","BK1141"],"gpt_icon":0},{"id":"2586476142","title":"昭衍新药：11月26日高管孙云霞减持股份合计10万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2586476142","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2586476142?lang=zh_cn&edition=full","pubTime":"2025-11-27 20:02","pubTimestamp":1764244929,"startTime":"0","endTime":"0","summary":"证券之星消息，根据11月27日市场公开信息、上市公司公告及交易所披露数据整理，昭衍新药最新董监高及相关人员股份变动情况：2025年11月26日公司董事孙云霞共减持公司股份10.0万股，占公司总股本为0.0133%。变动期间公司股价上涨1.62%，11月26日当日收盘报28.31元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025112700033441.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1576","BK0216","603127","06127","BK1141"],"gpt_icon":0},{"id":"2585108071","title":"每周股票复盘：昭衍新药（603127）董事高大鹏减持1.0万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2585108071","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2585108071?lang=zh_cn&edition=full","pubTime":"2025-11-23 02:02","pubTimestamp":1763834540,"startTime":"0","endTime":"0","summary":"截至2025年11月21日收盘，昭衍新药报收于27.4元，较上周的33.1元下跌17.22%。本周，昭衍新药11月17日盘中最高价报32.92元。股本股东变化高管增减持2025年11月20日，公司董事高大鹏减持昭衍新药股份1.0万股，占公司总股本0.0013%。变动期间公司股价下跌4.91%，当日收盘价为28.28元。公司公告汇总昭衍新药发布关于股东部分股份解除质押的公告：截至披露日，顾美芳持有公司10,322,035股，占总股本1.38%。解质后，顾美芳累计质押股份为5,000,000股，占其持股比例48.44%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025112300000393.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1141","BK0216","603127","BK1576","06127"],"gpt_icon":0},{"id":"2585954110","title":"昭衍新药：11月20日高管高大鹏减持股份合计10000股","url":"https://stock-news.laohu8.com/highlight/detail?id=2585954110","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2585954110?lang=zh_cn&edition=full","pubTime":"2025-11-21 20:02","pubTimestamp":1763726537,"startTime":"0","endTime":"0","summary":"证券之星消息，根据11月21日市场公开信息、上市公司公告及交易所披露数据整理，昭衍新药最新董监高及相关人员股份变动情况：2025年11月20日公司董事高大鹏共减持公司股份1.0万股，占公司总股本为0.0013%。变动期间公司股价下跌4.91%，11月20日当日收盘报28.28元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025112100034681.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["06127","603127","BK1576","BK1141","BK0216"],"gpt_icon":0},{"id":"2584201643","title":"昭衍新药(06127)获股东顾美芳解除质押140万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2584201643","media":"智通财经网","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2584201643?lang=zh_cn&edition=full","pubTime":"2025-11-17 16:55","pubTimestamp":1763369759,"startTime":"0","endTime":"0","summary":"智通财经APP讯，昭衍新药(06127)发布公告，2025年11月17日，公司接到股东顾美芳女士将其持有公司部分质押股份解除质押的通知，本次解质股份140万股。截至本公告披露日，顾美芳女士持有公司股份1032.2万股，占公司总股本的1.38%股;本次股份解除质押后，顾美芳女士持有公司股份累计质押数量为500万股，占其持股数量的48.44%。更多港股重磅资讯，下载智通财经app更多港股及海外理财资讯，请点击www.zhitongcaijing.com（搜索“智通财经”）；欲加入智通港股投资群，请加智通客服微信(ztcjkf)","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1369990.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["BK1576","BK1141","603127","BK0216","06127"],"gpt_icon":0},{"id":"2583659611","title":"每周股票复盘：昭衍新药（603127）拟取消监事会并修改章程","url":"https://stock-news.laohu8.com/highlight/detail?id=2583659611","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2583659611?lang=zh_cn&edition=full","pubTime":"2025-11-16 02:13","pubTimestamp":1763230391,"startTime":"0","endTime":"0","summary":"截至2025年11月14日收盘，昭衍新药报收于33.1元，较上周的32.49元上涨1.88%。本周，昭衍新药11月14日盘中最高价报34.13元。公司公告汇总昭衍新药2025年第二次临时股东大会会议资料北京昭衍新药研究中心股份有限公司拟取消监事会，其职权由董事会审计委员会行使，并相应修改《公司章程》。审议事项包括关于取消监事会并修改《公司章程》的议案、关于修订公司治理制度的多项子议案，以及关于选举第五届董事会非独立董事和独立董事的累积投票议案。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025111600000441.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["06127","BK1576","BK1141","BK0216","603127"],"gpt_icon":0},{"id":"2583033575","title":"昭衍新药：11月12日至11月13日高管高大鹏、孙云霞减持股份合计10.5万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2583033575","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2583033575?lang=zh_cn&edition=full","pubTime":"2025-11-14 20:02","pubTimestamp":1763121725,"startTime":"0","endTime":"0","summary":"证券之星消息，根据11月14日市场公开信息、上市公司公告及交易所披露数据整理，昭衍新药最新董监高及相关人员股份变动情况：2025年11月12日至2025年11月13日公司董事高大鹏、董事孙云霞共减持公司股份10.5万股，占公司总股本为0.014%。变动期间公司股价上涨3.45%，11月13日当日收盘报33.54元。该股最近90天内共有8家机构给出评级，买入评级7家，增持评级1家；过去90天内机构目标均价为39.75。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025111400036225.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0216","06127","BK1576","603127","BK1141"],"gpt_icon":0},{"id":"2580047323","title":"每周股票复盘：昭衍新药（603127）Q3净利降80.11%，拟取消监事会","url":"https://stock-news.laohu8.com/highlight/detail?id=2580047323","media":"证券之星","labels":["executive","dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2580047323?lang=zh_cn&edition=full","pubTime":"2025-11-02 02:25","pubTimestamp":1762021513,"startTime":"0","endTime":"0","summary":"截至2025年10月31日收盘，昭衍新药报收于36.99元，较上周的32.45元上涨13.99%。本周，昭衍新药10月31日盘中最高价报37.98元。2025年第三季度，公司单季度主营收入3.16亿元，同比下降34.87%；单季度归母净利润1977.37万元，同比下降80.11%；单季度扣非净利润599.26万元，同比下降92.94%。公司公告汇总昭衍新药第四届董事会第十六次会议于2025年10月30日召开，审议通过《2025年第三季度报告》。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025110200000376.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"executive,dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0216","06127","BK1141","603127","BK1576"],"gpt_icon":0},{"id":"2579243406","title":"港股异动 | 昭衍新药(06127)涨超4% 前三季度归母净利润8070.61万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2579243406","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2579243406?lang=zh_cn&edition=full","pubTime":"2025-10-31 15:00","pubTimestamp":1761894033,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，昭衍新药(06127)涨超4%，截至发稿，涨4.34%，报21.66港元，成交额2.09亿港元。消息面上，昭衍新药发布公告，2025年前三季度该集团取得营业收入9.85亿元，同比减少26.23%；归母净利润8070.61万元，去年同期亏损7030.71万元。公告指出，受多种因素综合影响，公司前三季度累计新签订单金额约人民币16.4亿元，截止本报告期末，公司整体在手订单金额约人民币25亿元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1363578.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["603127","06127"],"gpt_icon":0},{"id":"2579575123","title":"昭衍新药（603127）披露拟取消监事会并由审计委员会行使职权，10月30日股价上涨1.7%","url":"https://stock-news.laohu8.com/highlight/detail?id=2579575123","media":"证券之星","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2579575123?lang=zh_cn&edition=full","pubTime":"2025-10-30 22:08","pubTimestamp":1761833337,"startTime":"0","endTime":"0","summary":"截至2025年10月30日收盘，昭衍新药报收于35.37元，较前一交易日上涨1.7%，最新总市值为265.09亿元。该股当日开盘34.78元，最高35.9元，最低33.88元，成交额达10.1亿元，换手率为4.61%。根据公司近日发布的第四届董事会第十六次会议决议公告，北京昭衍新药研究中心股份有限公司于2025年10月30日召开会议，审议通过多项议案。其中，会议审议通过取消监事会，其职权由董事会审计委员会行使，并相应修订《公司章程》及相关治理制度。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025103000044717.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["06127","603127","BK1141","BK1576","BK0216"],"gpt_icon":0},{"id":"2579420611","title":"图解昭衍新药三季报：第三季度单季净利润同比下降80.11%","url":"https://stock-news.laohu8.com/highlight/detail?id=2579420611","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2579420611?lang=zh_cn&edition=full","pubTime":"2025-10-30 21:06","pubTimestamp":1761829614,"startTime":"0","endTime":"0","summary":"证券之星消息，昭衍新药2025年三季报显示，前三季度公司主营收入9.85亿元，同比下降26.23%；归母净利润8070.61万元，同比上升214.79%；扣非净利润2904.47万元，同比上升125.6%；其中2025年第三季度，公司单季度主营收入3.16亿元，同比下降34.87%；单季度归母净利润1977.37万元，同比下降80.11%；单季度扣非净利润599.26万元，同比下降92.94%；负债率14.81%，投资收益2003.33万元，财务费用-5291.34万元，毛利率21.55%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025103000042255.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["603127","06127"],"gpt_icon":0},{"id":"2579976968","title":"昭衍新药(06127)股东顾美芳解除质押700万股股份","url":"https://stock-news.laohu8.com/highlight/detail?id=2579976968","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2579976968?lang=zh_cn&edition=full","pubTime":"2025-10-29 18:22","pubTimestamp":1761733328,"startTime":"0","endTime":"0","summary":"智通财经APP讯，昭衍新药(06127)公布，2025 年 10 月 29 日，公司接到股东顾美芳女士将其持有公司质押股份解除质押的通知，涉及解除质押700万股股份。本次解除质押股份后，部分股份于同日进行再次质押。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1362079.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1576","BK0216","603127","06127","BK1141"],"gpt_icon":0},{"id":"2576059182","title":"昭衍新药（603127）披露董事会召开日期，10月17日股价下跌1.81%","url":"https://stock-news.laohu8.com/highlight/detail?id=2576059182","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2576059182?lang=zh_cn&edition=full","pubTime":"2025-10-17 22:26","pubTimestamp":1760711175,"startTime":"0","endTime":"0","summary":"截至2025年10月17日收盘，昭衍新药报收于32.5元，较前一交易日下跌1.81%，最新总市值为243.58亿元。该股当日开盘33.13元，最高33.6元，最低32.34元，成交额达4.85亿元，换手率为2.33%。公司近日发布公告称，董事会谨定于2025年10月30日（星期四）举行会议，以考虑及通过本集团截至2025年9月30日止九个月之第三季度业绩及其发布。公告由公司主席冯宇霞于2025年10月17日在中国北京发出。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025101700038467.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["06127","BK1576","BK0216","603127","BK1141"],"gpt_icon":0},{"id":"2575227327","title":"港股异动 | 昭衍新药(06127)涨超3% 近日助力益科思特创新双特异性抗体YK012获批美国FDA IND","url":"https://stock-news.laohu8.com/highlight/detail?id=2575227327","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2575227327?lang=zh_cn&edition=full","pubTime":"2025-10-15 10:56","pubTimestamp":1760496977,"startTime":"0","endTime":"0","summary":"消息面上，据昭衍新药官微消息，近日，益科思特自主研发的靶向CD19/CD3的创新双特异性抗体YK012.正式获得美国食品药品监督管理局的临床试验批准，用于治疗原发性膜性肾病。据介绍，YK012的研发依托益科思特“北京总部+美国全资子公司Excyte LLC”双中心布局，此次FDA IND获批后，公司将逐步启动国际多中心临床研究，与中国已开展的多中心试验形成数据互补，加速全球研发进程。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1355171.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["06127","BK0216","BK1576","BK1141","603127"],"gpt_icon":0},{"id":"2574240452","title":"每周股票复盘：昭衍新药（603127）高管减持9.45万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2574240452","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2574240452?lang=zh_cn&edition=full","pubTime":"2025-10-12 01:17","pubTimestamp":1760203030,"startTime":"0","endTime":"0","summary":"截至2025年10月10日收盘，昭衍新药报收于33.7元，较上周的35.3元下跌4.53%。本周，昭衍新药10月9日盘中最高价报35.9元。本周关注点股本股东变化：公司董事及高管于9月30日合计减持9.45万股，占总股本0.0127%。公司公告汇总H股公告：9月月报表北京昭衍新药研究中心股份有限公司截至2025年9月30日的证券变动月报表显示，H股和A股的法定/注册股本均无变动。H股本月结存为118,995,206股，每股面值人民币1元；A股本月结存为630,482,128股，每股面值人民币1元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025101200000144.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1576","BK1141","603127","06127","BK0216"],"gpt_icon":0},{"id":"2574542191","title":"昭衍新药：9月30日高管高大鹏、孙云霞、顾静良、李叶减持股份合计9.45万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2574542191","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2574542191?lang=zh_cn&edition=full","pubTime":"2025-10-09 20:02","pubTimestamp":1760011346,"startTime":"0","endTime":"0","summary":"证券之星消息，根据10月9日市场公开信息、上市公司公告及交易所披露数据整理，昭衍新药最新董监高及相关人员股份变动情况：2025年9月30日公司董事,高级管理人员高大鹏、董事,高级管理人员孙云霞、董事,高级管理人员顾静良、监事李叶共减持公司股份9.45万股，占公司总股本为0.0127%。变动期间公司股价下跌0.03%，9月30日当日收盘报35.3元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025100900030418.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0216","06127","BK1576","BK1141","603127"],"gpt_icon":0},{"id":"2570099552","title":"FIDELITY FUNDS减持昭衍新药(06127)44.57万股 每股作价约24.39港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2570099552","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2570099552?lang=zh_cn&edition=full","pubTime":"2025-09-25 18:52","pubTimestamp":1758797575,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，香港联交所最新数据显示，9月22日，FIDELITY FUNDS减持昭衍新药(06127)44.57万股，每股作价24.3867港元，总金额约为1086.92万港元。减持后最新持股数目为713.03万股，最新持股比例为5.99%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1349476.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["06127","BK1576","BK0216","603127","BK1141"],"gpt_icon":0},{"id":"2569798497","title":"9月23日昭衍新药跌6.04%，易方达创新驱动灵活配置混合基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2569798497","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2569798497?lang=zh_cn&edition=full","pubTime":"2025-09-23 16:32","pubTimestamp":1758616370,"startTime":"0","endTime":"0","summary":"证券之星消息，9月23日昭衍新药跌6.04%，收盘报36.53元，换手率6.23%，成交量39.3万手，成交额14.56亿元。根据2025基金半年报公募基金重仓股数据，重仓该股的公募基金共14家，其中持有数量最多的公募基金为易方达基金的易方达创新驱动灵活配置混合。易方达创新驱动灵活配置混合目前规模为18.2亿元，最新净值2.119，较上一交易日上涨2.27%，近一年上涨76.29%。贾健在任的基金产品包括:易方达瑞程灵活配置混合A，管理时间为2022年5月7日至今，期间收益率为18.46%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025092300025889.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1141","BK0216","BK1576","06127","603127"],"gpt_icon":0},{"id":"2569761972","title":"昭衍新药遭富达国际减持161.08万股 每股均价约21.57港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2569761972","media":"新浪港股","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2569761972?lang=zh_cn&edition=full","pubTime":"2025-09-22 08:13","pubTimestamp":1758499980,"startTime":"0","endTime":"0","summary":"热点栏目\n\n自选股\n数据中心\n行情中心\n资金流向\n模拟交易\n\n客户端\n\n\n 香港联交所最新资料显示，9月16日，富达国际减持昭衍新药（06127）161.08万股，每股均价21.5742港元，总金额约为3475.17万港元。减持后最新持股数目为1145.48万股，最新持股比例为9.63%。\n\n\n海量资讯、精准解读，尽在新浪财经APP\n\n责任编辑：卢昱君","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/ggscyd/2025-09-22/doc-infrikpu1827004.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK1141","603127","BK4539","LU0359201612.USD","IE00B12V2V27.USD","LU0359202008.SGD","BK4526","LU1023057109.AUD","BK1576","IE00BYQNZ168.SGD","LU0502904849.HKD","IE00BYTNYN87.SGD","LU0572944931.SGD","LU0359201885.HKD","YMM","BK4022","BK4548","BK4503","LU2242644610.SGD","LU0327786744.USD","BK4232","06127","LU2247934214.USD","SG9999011746.SGD","LU0456842615.SGD","LU0455707207.USD","BK0216"],"gpt_icon":0}],"profile":{"ret":0,"serverTime":1764948750023,"stockEarnings":[{"period":"1week","weight":-0.0014},{"period":"1month","weight":-0.1911},{"period":"3month","weight":-0.1808},{"period":"6month","weight":0.4793},{"period":"1year","weight":0.6147},{"period":"ytd","weight":0.6768}],"compareEarnings":[{"period":"1week","weight":0.0001},{"period":"1month","weight":-0.0213},{"period":"3month","weight":0.0166},{"period":"6month","weight":0.1449},{"period":"1year","weight":0.1519},{"period":"ytd","weight":0.1563}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"北京昭衍新药研究中心股份有限公司","boardCode":"AI0073","boardName":"研究和试验发展","stockholders":"0人","perCapita":"--","listingDate":"2017-08-25","address":"北京市大兴区北京经济技术开发区荣京东街甲5号","registeredCapital":"74947万元","survey":" 北京昭衍新药研究中心股份有限公司的主营业务是以药物非临床安全性评价服务为主的药物临床前研究服务和实验动物及附属产品的销售业务。公司的主要产品是药物非临床研究服务、临床服务及其他、实验模型供应。","listedPrice":12.51},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.35.9","shortVersion":"4.35.9","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"昭衍新药(603127)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供昭衍新药(603127)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"昭衍新药,603127,昭衍新药股票,昭衍新药股票老虎,昭衍新药股票老虎国际,昭衍新药行情,昭衍新药股票行情,昭衍新药股价,昭衍新药股市,昭衍新药股票价格,昭衍新药股票交易,昭衍新药股票购买,昭衍新药股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"昭衍新药(603127)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供昭衍新药(603127)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}